| # | Title | Journal | Year | Citations |
|---|
| 1 | Role of angiogenesis in tumor growth and metastasis | Seminars in Oncology | 2002 | 2,158 |
| 2 | Phase I studies with bendamustine: An update | Seminars in Oncology | 2002 | 1,327 |
| 3 | Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia | Seminars in Oncology | 2003 | 841 |
| 4 | Role of angiogenesis in tumor growth and metastasis | Seminars in Oncology | 2002 | 829 |
| 5 | Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination | Seminars in Oncology | 1995 | 773 |
| 6 | Molecular, biochemical, and cellular pharmacology of pemetrexed | Seminars in Oncology | 2002 | 743 |
| 7 | Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications | Seminars in Oncology | 2002 | 677 |
| 8 | Epidermal Growth Factor Receptor Targeting in Cancer | Seminars in Oncology | 2006 | 645 |
| 9 | Breast Cancer Before Age 40 Years | Seminars in Oncology | 2009 | 574 |
| 10 | Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society | Seminars in Oncology | 1991 | 556 |
| 11 | The anthracyclines: will we ever find a better doxorubicin? | Seminars in Oncology | 1992 | 522 |
| 12 | The National Cancer Institute: cancer drug discovery and development program | Seminars in Oncology | 1992 | 520 |
| 13 | Overview of non-Hodgkin[apos ]s lymphoma: Biology, staging, and treatment | Seminars in Oncology | 2003 | 512 |
| 14 | Multiple myeloma epidemiology and survival: A unique malignancy | Seminars in Oncology | 2016 | 492 |
| 15 | Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) | Seminars in Oncology | 1999 | 487 |
| 16 | Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity | Seminars in Oncology | 2004 | 480 |
| 17 | Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults | Seminars in Oncology | 1980 | 472 |
| 18 | Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience | Seminars in Oncology | 2001 | 463 |
| 19 | A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer | Seminars in Oncology | 2003 | 453 |
| 20 | Past and present treatment of pancreatic adenocarcinoma: Chemotherapy as a standard treatment modality | Seminars in Oncology | 2002 | 451 |
| 21 | The changing epidemiology of esophageal cancer | Seminars in Oncology | 1999 | 443 |
| 22 | Cancer Prevention With Natural Compounds | Seminars in Oncology | 2010 | 425 |
| 23 | An overview of HER2 | Seminars in Oncology | 2001 | 411 |
| 24 | Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results | Seminars in Oncology | 1998 | 399 |
| 25 | Oxygenation status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy | Seminars in Oncology | 2001 | 389 |
| 26 | The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment | Seminars in Oncology | 2015 | 388 |
| 27 | Factors influencing survival in high-grade gliomas | Seminars in Oncology | 2003 | 371 |
| 28 | Gemcitabine: preclinical pharmacology and mechanisms of action | Seminars in Oncology | 1996 | 365 |
| 29 | Oxaliplatin-related side effects: Characteristics and management | Seminars in Oncology | 2002 | 346 |
| 30 | Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy | Seminars in Oncology | 2006 | 343 |
| 31 | Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience | Seminars in Oncology | 2001 | 339 |
| 32 | The pathogenesis of mesothelioma | Seminars in Oncology | 2002 | 330 |
| 33 | Chemotherapy for advanced renal-cell carcinoma: 1983-1993 | Seminars in Oncology | 1995 | 327 |
| 34 | Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy | Seminars in Oncology | 2004 | 326 |
| 35 | Myelodysplastic syndromes: introduction | Seminars in Oncology | 1992 | 324 |
| 36 | Role of Raf Kinase in Cancer: Therapeutic Potential of Targeting the Raf/MEK/ERK Signal Transduction Pathway | Seminars in Oncology | 2006 | 319 |
| 37 | Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures | Seminars in Oncology | 2002 | 316 |
| 38 | Cancer in older persons: an international issue in an aging world | Seminars in Oncology | 2004 | 315 |
| 39 | Pemetrexed: Single-agent and combination phase I study overview | Seminars in Oncology | 2002 | 315 |
| 40 | Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia | Seminars in Oncology | 2003 | 304 |
| 41 | Cyclooxygenase-2 inhibitors in colorectal cancer | Seminars in Oncology | 2003 | 304 |
| 42 | Cardiotoxic Consequences of Anthracycline-Containing Therapy in Patients With Breast Cancer | Seminars in Oncology | 2006 | 298 |
| 43 | Rituximab: Mechanism of action and resistance | Seminars in Oncology | 2002 | 297 |
| 44 | Epidemiology of upper gastrointestinal malignancies | Seminars in Oncology | 2004 | 296 |
| 45 | Taxol: the first of the taxanes, an important new class of antitumor agents | Seminars in Oncology | 1992 | 286 |
| 46 | Molecular genetics of small cell lung carcinoma | Seminars in Oncology | 2001 | 283 |
| 47 | Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow Transplantation | Seminars in Oncology | 2012 | 282 |
| 48 | Natural history of and therapy for the indolent non-Hodgkin's lymphomas | Seminars in Oncology | 1993 | 282 |
| 49 | An Update on Cancer- and Chemotherapy-Related Cognitive Dysfunction: Current Status | Seminars in Oncology | 2011 | 280 |
| 50 | Adult multicenter trials using dexrazoxane to protect against cardiac toxicity | Seminars in Oncology | 1998 | 277 |
